[1]
|
Bania, J., Gatti, E., Lelouard, H., et al. (2003) Human cathepsin S, but not cathepsin L, degrades efficiently MHC class II-associated invariant chain in nonprofessional APCs. Proceedings of the National Academy of Sciences, 100, 6664-6669. doi:10.1073/pnas.1131604100
|
[2]
|
Mohamed, M.M. and Sloane B.F. (2006) Cysteine cathepsins: Multifunctional enzymes in cancer. Nature Reviews, 6, 764-775. doi:10.1038/nrc1949
|
[3]
|
Lindahl, C., Simonsson, M., Bergh, A., et al. (2009) Increased levels of macrophage-secreted cathepsin S during prostate cancer progression in TRAMP mice and patients. Cancer Genomics Proteomics, 6, 149-159.
|
[4]
|
Paraoan, L., Gray, D., Hiscott, P., et al. (2009) Cathepsin S and its inhibitor cystatin C: Imbalance in uveal melanoma. Frontiers in Bioscience, 14, 2504-2513.
doi:10.2741/3393
|
[5]
|
Xu, J., Li, D., Ke, Z., et al. (2009) Cathepsin S is aberrantly overexpressed in human hepatocellular carcinoma. Molecular Medicine Reports, 2, 713-718.
|
[6]
|
Flannery, T., McQuaid, S., McGoohan, C., et al. (2006) Cathepsin S expression: An independent prognostic factor in glioblastoma tumours—A pilot study. International Journal of Cancer, 15, 854-860. doi:10.1002/ijc.21911
|
[7]
|
Gormley, J.A., Hegarty, S.M., O’Grady, A., et al. (2011) The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: A pilot study. British Journal of Cancer, 105, 1487-1494.
doi:10.1038/bjc.2011.408
|
[8]
|
Kwok, H.F., Buick, R.J., Kuehn, D., et al. (2011) Antibody targeting of Cathepsin S induces antibody-dependent cellular cytotoxicity. Molecular Cancer, 14, 147.
doi:10.1186/1476-4598-10-147
|
[9]
|
Burden, R.E., Gormley, J.A., Jaquin, T.J., et al. (2009) Antibody-mediated inhibition of cathepsin S blocks colorectal tumor invasion and angiogenesis. Clincial Cancer Research, 15, 6042-6051.
doi:10.1158/1078-0432.CCR-09-1262
|
[10]
|
Wang, B., Sun, J., Kitamoto, S., et al. (2006) Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. Journal of Biological Chemistry, 281, 6020-6029. doi:10.1074/jbc.M509134200
|
[11]
|
Ryschich, E., Lizdenis, P., Ittrich, C., et al. (2006) Molecular fingerprinting and autocrine growth regulation of endothelial cells in a murine model of hepatocellular carcinoma. Cancer Research, 66, 198-211.
doi:10.1158/0008-5472.CAN-05-1636
|
[12]
|
Gocheva, V., Zeng, W., Ke, D., et al. (2006) Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes & Development, 20, 543-556.
doi:10.1101/gad.1407406
|
[13]
|
Ward, C., Kuehn, D., Burden, R.E., et al. (2010) Antibody targeting of cathepsin S inhibits angiogenesis and synergistically enhances anti-VEGF. PLoS One, 5, Article ID: e12543. doi:10.1371/journal.pone.0012543
|
[14]
|
Burden, R.E., Gormley, J.A., Kuehn, D., et al. (2012) Inhibition of Cathepsin S by Fsn0503 enhances the efficacy of chemotherapy in colorectal carcinomas. Biochimie, 94, 487-493. doi:10.1016/j.biochi.2011.08.017
|
[15]
|
Thurston, D.E. (2007) Chemistry and pharmacology of anticancer drugs. CRC Press (Taylor & Francis), Florida.
|
[16]
|
Schrama, D., Reisfeld, R.A. and Becker, J.C. (2006) Antibody targeted drugs as cancer therapeutics. Nature Reviews Drug Discovery, 5, 147-159. doi:10.1038/nrd1957
|
[17]
|
Pastan, I., Hassan, R., Fitzgerald, D.J., et al. (2006) Immunotoxin therapy of cancer. Nature Reviews Cancer, 6, 559-565. doi:10.1038/nrc1891
|
[18]
|
Zafir-Lavie, I., Michaeli, Y. and Reiter, Y. (2007) Novel antibodies as anticancer agents. Oncogene, 26, 3714-3733.
doi:10.1038/sj.onc.1210372
|